These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16610342)

  • 1. Cardiac Na+ channels as therapeutic targets for antiarrhythmic agents.
    Glaaser IW; Clancy CE
    Handb Exp Pharmacol; 2006; (171):99-121. PubMed ID: 16610342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
    Liu H; Tateyama M; Clancy CE; Abriel H; Kass RS
    J Gen Physiol; 2002 Jul; 120(1):39-51. PubMed ID: 12084774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacology of voltage-gated sodium channels in sensory neurones.
    Docherty RJ; Farmer CE
    Handb Exp Pharmacol; 2009; (194):519-61. PubMed ID: 19655117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium channel molecular conformations and antiarrhythmic drug affinity.
    Sheets MF; Fozzard HA; Lipkind GM; Hanck DA
    Trends Cardiovasc Med; 2010 Jan; 20(1):16-21. PubMed ID: 20685573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac-specific external paths for lidocaine, defined by isoform-specific residues, accelerate recovery from use-dependent block.
    Lee PJ; Sunami A; Fozzard HA
    Circ Res; 2001 Nov; 89(11):1014-21. PubMed ID: 11717158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Block and modulation of cardiac Na+ channels by antiarrhythmic drugs, neurotransmitters and hormones.
    Grant AO; Wendt DJ
    Trends Pharmacol Sci; 1992 Sep; 13(9):352-8. PubMed ID: 1356284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
    Fredj S; Sampson KJ; Liu H; Kass RS
    Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.
    Walker MJA; Hayes ES; Saint DA; Adaikan G; Abraham S; Goldin AL; Beatch GN; MacLeod BA; Wall RA; Pugsley MK
    Biomed Pharmacother; 2018 Oct; 106():510-522. PubMed ID: 29990839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel.
    Qu Y; Rogers J; Tanada T; Scheuer T; Catterall WA
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11839-43. PubMed ID: 8524860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium channel blockers in the treatment of ventricular arrhythmias: different effects in the normal, ischaemic or failing heart?
    Haverkamp W; Hindricks G; Fechtrup C; Borggrefe M; Breithardt G
    Eur Heart J; 1991 Dec; 12 Suppl F():10-7. PubMed ID: 1666550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
    Wang GK; Russell C; Wang SY
    J Physiol; 2004 Feb; 554(Pt 3):621-33. PubMed ID: 14608007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide.
    Wang GK; Russell C; Wang SY
    J Gen Physiol; 2003 Sep; 122(3):365-74. PubMed ID: 12913091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.
    Ragsdale DS; McPhee JC; Scheuer T; Catterall WA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9270-5. PubMed ID: 8799190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic overlap of cardiac sodium channelopathies: individual-specific or mutation-specific?
    Makita N
    Circ J; 2009 May; 73(5):810-7. PubMed ID: 19336922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access.
    Sasaki K; Makita N; Sunami A; Sakurada H; Shirai N; Yokoi H; Kimura A; Tohse N; Hiraoka M; Kitabatake A
    Mol Pharmacol; 2004 Aug; 66(2):330-6. PubMed ID: 15266024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels.
    Sheets MF; Hanck DA
    J Physiol; 2007 Jul; 582(Pt 1):317-34. PubMed ID: 17510181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential interaction of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel alpha-subunits.
    Weiser T; Qu Y; Catterall WA; Scheuer T
    Mol Pharmacol; 1999 Dec; 56(6):1238-44. PubMed ID: 10570051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs.
    Itoh H; Shimizu M; Takata S; Mabuchi H; Imoto K
    J Cardiovasc Electrophysiol; 2005 May; 16(5):486-93. PubMed ID: 15877619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.